ArticlePloS one2013
Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms.Nature reviews. Neurology · 2025Review
- Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.Nature communications · 2023Article
- Alzheimer disease neuropathology in a patient previously treated with aducanumab.Acta neuropathologica · 2022Article
- A History of Senile Plaques: From Alzheimer to Amyloid Imaging.Journal of neuropathology and experimental neurology · 2022Article
- Basal lamina changes in neurodegenerative disorders.Molecular neurodegeneration · 2021Review
- Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.Molecular neurodegeneration · 2016Review
- Improvement of Electroacupuncture on APP/PS1 Transgenic Mice in Spatial Learning and Memory Probably due to Expression of AEvidence-based complementary and alternative medicine : eCAM · 2016Article
- Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab.American journal of neurodegenerative disease · 2016Article
- Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2015Article
- Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Neuropathology : official journal of the Japanese Society of Neuropathology · 2015Article
- Clinical Neuropathological Analysis of 10 Cases of Cerebral Amyloid Angiopathy-Related Cerebral Lobar Hemorrhage.Journal of Korean Neurosurgical Society · 2015Article
- Alzheimer's disease and immunotherapy: what is wrong with clinical trials?ImmunoTargets and therapy · 2015Review
- Characterization of a brain permeant fluorescent molecule and visualization of Aβ parenchymal plaques, using real-time multiphoton imaging in transgenic mice.Organic letters · 2014Article
- Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.Journal of neurochemistry · 2014Article
- Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticity.Frontiers in pharmacology · 2014Article
- Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance.Frontiers in aging neuroscience · 2014Review
- Harnessing the immune system for treatment and detection of tau pathology.Journal of Alzheimer's disease : JAD · 2014Review
- Cerebral amyloid PET imaging in Alzheimer's disease.Acta neuropathologica · 2013Review
- Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.ImmunoTargets and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The characteristic neuropathological changes associated with Alzheimer's disease (AD) and other lines of evidence support the amyloid cascade hypothesis. Viewing amyloid deposits as the prime instigator of dementia has now led to clinical trials of multiple strategies to remove or prevent their formation. We performed neuropathological and biochemical assessments of 3 subjects treated with bapineuzumab infusions. Histological analyses were conducted to quantify amyloid plaque densities, Braak stages and the extent of cerebral amyloid angiopathy (CAA). Amyloid-β (Aβ) species in frontal and temporal lobe samples were quantified by ELISA. Western blots of amyloid-β precursor protein (AβPP) and its C-terminal (CT) fragments as well as tau species were performed. Bapineuzumab-treated (Bapi-AD) subjects were compared to non-immunized age-matched subjects with AD (NI-AD) and non-demented control (NDC) cases. Our study revealed that Bapi-AD subjects exhibited overall amyloid plaque densities similar to those of NI-AD cases. In addition, CAA was moderate to severe in NI-AD and Bapi-AD patients. Although histologically-demonstrable leptomeningeal, cerebrovascular and neuroparenchymal-amyloid densities all appeared unaffected by treatment, Aβ peptide profiles were significantly altered in Bapi-AD subjects. There was a trend for reduction in total Aβ42 levels as well as an increase in Aβ40 which led to a corresponding significant decrease in Aβ42:Aβ40 ratio in comparison to NI-AD subjects. There were no differences in the levels of AβPP, CT99 and CT83 or tau species between Bapi-AD and NI-AD subjects. The remarkable alteration in Aβ profiles reveals a dynamic amyloid production in which removal and depositional processes were apparently perturbed by bapineuzumab therapy. Despite the alteration in biochemical composition, all 3 immunized subjects exhibited continued cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.